IQVIA Holdings, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ari Bousbib
- Full Time Employees
- 93,000
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 2400 Ellis Road Durham NC United States 27703
- IPO Date
- May 9, 2013
- CIK
- 0001478242
- Website
- iqvia.com
- Similar Companies
- Business
- IQVIA Holdings Inc operates as a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries. The company offers a comprehensive portfolio including clinical trial services; commercial insights; healthcare intelligence; real-world evidence generation; and advanced data analytics powered by IQVIA Connected Intelligence™, Healthcare-grade AI™, and big data resources. Its technology solutions encompass software platforms for orchestrated customer engagement, data management, and commercial orchestration, supported by partnerships with leading technology providers such as NVIDIA and Veeva Systems. IQVIA's service offerings span drug development, regulatory consulting, market access, and patient centricity solutions, targeting pharmaceutical, biotechnology, and medical device companies worldwide. Headquartered in Durham, North Carolina, and founded through the 2016 merger of Quintiles and IMS Health, IQVIA operates in more than 100 countries with approximately 88,000 employees. Recent company developments include a strategic partnership with NVIDIA to integrate generative and agentic AI within clinical research workflows, accelerating innovation and efficiency in drug development. IQVIA also expanded a clinical and commercial collaboration with Veeva Technologies to enhance interoperability and deliver streamlined solutions for customers in clinical development and commercialization. In 2024 and 2025, IQVIA advanced its healthcare data analytics capabilities through acquisitions of healthcare technology firms, reinforcing its technology portfolio and enabling broader service offerings. Additionally, the company continues to support pharmaceutical product launches globally, tracking and analyzing launch excellence to optimize commercial success across multiple therapeutic areas. IQVIA's ongoing investments in AI and integrated technology ecosystems position it at the forefront of healthcare intelligence and life sciences services innovation.
Company News
Artisan Global Value Fund Q3 2026 Portfolio Discussion
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
IQVIA Holdings Inc. $IQV Stock Purchased by Citizens Financial Group Inc. RI
What IQVIA (IQV) Said on Its Q3 Earnings Call
IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y
IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates
IQVIA Reports Third-Quarter 2026 Results
IQVIA Reports Third-Quarter 2026 Results
IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know
IQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires Execution
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
IQVIA Holdings Inc. $IQV Stock: Maia Wealth LLC Reduces Stake
First Citizens Bank & Trust Co. Makes New $1.39 Million Investment in IQVIA Holdings Inc. $IQV
IQVIA Selects Veeva Clinical Operations Applications
IQVIA Selects Veeva Clinical Operations Applications
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes
IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity
Rep. Kevin Hern Unloads Shares of Honeywell International Inc. (NASDAQ:HON)